Insulin secretion in type 2 diabetes: clinical aspects

Area of Science:

• Endocrinology
• Metabolic Diseases
• Genetics

Background:

• Type 2 diabetes is characterized by insulin secretion abnormalities and impaired insulin action.
• Insulin resistance alone does not cause type 2 diabetes; beta-cell defects are essential.
• Early-stage type 2 diabetes and impaired glucose tolerance invariably involve beta-cell secretion defects.

Purpose of the Study:

• To review methods for evaluating beta-cell function and their limitations.
• To explore the relationship between beta-cell function tests and genetic factors in type 2 diabetes.
• To discuss the potential of genetic mapping for improving clinical evaluation of insulin secretion.

Main Methods:

• Review of current methods for assessing beta-cell function.
• Analysis of the limitations of existing insulin secretion tests.
• Examination of the correlation between genetic knowledge and beta-cell function.

Main Results:

• Beta-cell secretion defects are present in impaired glucose tolerance and early type 2 diabetes.
• Abnormalities in biphasic insulin secretion, including loss of the first phase, are common early findings.
• Current insulin secretion tests cannot be precisely correlated with type 2 diabetes diagnosis without etiological biological parameters.

Conclusions:

• Beta-cell dysfunction is a key component of type 2 diabetes pathogenesis.
• Type 1 diabetes serves as a valuable model for understanding type 2 diabetes.
• Future advancements in individual genetic mapping may enable reliable clinical interpretation of insulin secretion tests.